Ziltivekimab in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the ATHENA and HERMES trials.

Mendieta G, Ridker PM, Borlaug BA, Ducharme A, Lam CSP, Voors AA, Auerbach P, Cikes M, Fudim M, Hvelplund A, Michelsen MM, Petrie MC

Open source

DOI: 10.1093/ejhf/xuag153
Published: 2026 Sep 15
Container: European journal of heart failure
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/ejhf/xuag153,
  title = {Ziltivekimab in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the ATHENA and HERMES trials.},
  author = {Mendieta G and Ridker PM and Borlaug BA and Ducharme A and Lam CSP and Voors AA and Auerbach P and Cikes M and Fudim M and Hvelplund A and Michelsen MM and Petrie MC},
  year = {2026},
  journal = {European journal of heart failure},
  doi = {10.1093/ejhf/xuag153},
  url = {https://doi.org/10.1093/ejhf/xuag153}
}

RIS

TY  - JOUR
TI  - Ziltivekimab in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the ATHENA and HERMES trials.
AU  - Mendieta G
AU  - Ridker PM
AU  - Borlaug BA
AU  - Ducharme A
AU  - Lam CSP
AU  - Voors AA
AU  - Auerbach P
AU  - Cikes M
AU  - Fudim M
AU  - Hvelplund A
AU  - Michelsen MM
AU  - Petrie MC
PY  - 2026
JO  - European journal of heart failure
DO  - 10.1093/ejhf/xuag153
UR  - https://doi.org/10.1093/ejhf/xuag153
ER  -

APA

G, M., PM, R., BA, B., A, D., CSP, L., AA, V., P, A., M, C., M, F., A, H., MM, M., & MC, P. (2026). Ziltivekimab in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the ATHENA and HERMES trials.. European journal of heart failure. https://doi.org/10.1093/ejhf/xuag153

Source records

pubmed · retrieved 2026-09-26T00:51:12.869Z